Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome

Volume: 365, Issue: 8, Pages: 699 - 708
Published: Aug 24, 2011
Abstract
The addition of apixaban, at a dose of 5 mg twice daily, to antiplatelet therapy in high-risk patients after an acute coronary syndrome increased the number of major bleeding events without a significant reduction in recurrent ischemic events. (Funded by Bristol-Myers Squibb and Pfizer; APPRAISE-2 ClinicalTrials.gov number,...
Paper Details
Title
Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome
Published Date
Aug 24, 2011
Volume
365
Issue
8
Pages
699 - 708
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.